Overview

* Rhythm Pharmaceuticals Q2 2025 product revenue rises 67% yr/yr to $48.5 mln

* However, net loss widens to $46.6 mln

* Co raised $189.2 mln in upsized public offering, strengthening financial position

Outlook

* Rhythm expects Q3 2025 regulatory submissions for setmelanotide

* Company anticipates $285 mln to $315 mln in 2025 Non-GAAP Operating Expenses

* Rhythm plans to disclose Phase 2 Prader-Willi trial results in H2 2025

* Company expects cash reserves to fund operations for at least 24 months

Result Drivers

* IMCIVREE SALES - Revenue growth driven by increased sales of IMCIVREE for Bardet-Biedl syndrome treatment

* CLINICAL TRIAL SUCCESS - Positive Phase 2 and Phase 3 trial results for bivamelagon and setmelanotide in acquired hypothalamic obesity

* EXPENSES - R&D and SG&A expenses rose sharply, affecting net income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $48.50

Product mln

Revenue

Q2 Net Miss -$46.63 -$41.30

Income mln mln (11

Analysts

)

Q2 -$45.30

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc ( RYTM ) is $103.50, about 12.8% above its August 4 closing price of $90.24

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)